Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
about
Carbapenems: past, present, and futureColistin for lung infection: an updateNew antibiotic molecules: bypassing the membrane barrier of gram negative bacteria increases the activity of peptide deformylase inhibitorsBiology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment OptionsSynergy among antibacterial peptides and between peptides and small-molecule antibiotics.Structural changes and differentially expressed genes in Pseudomonas aeruginosa exposed to meropenem-ciprofloxacin combination.Colistin in the 21st century.Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients.Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearanceCombination therapy for treatment of infections with gram-negative bacteria.Optimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaPolymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.New information about the polymyxin/colistin class of antibiotics.Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria.Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists.Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.Revisiting eukaryotic anti-infective biotherapeutics.Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenemsDynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates.Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniaeActivity of levofloxacin alone and in combination with a DnaK inhibitor against gram-negative rods, including levofloxacin-resistant strains.Successful management of an outbreak due to carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit.Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.Pharmacological Inhibition of the Pseudomonas aeruginosa MvfR Quorum-Sensing System Interferes with Biofilm Formation and Potentiates Antibiotic-Mediated Biofilm Disruption.Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study.Synergy effect of meropenem-based combinations against : a systematic review and meta-analysis
P2860
Q24634999-8430B97E-E0BC-4B0E-9B74-D0834B53211DQ28082041-56036E3E-7BF8-4C97-8E84-50B86C3D305DQ28475848-939E385F-3A61-4444-85E5-4D264E1B65B2Q30235064-EEAA653C-261A-4235-A222-FC4665E36E4EQ33593511-0E7C421B-3670-4028-BD76-D9C4B046A3F1Q33798601-512E1E96-BBC7-4A0F-B6E5-6FECED8C9BB2Q33847509-38F2D478-5D7E-4064-8C4F-357071DFDCE8Q33882361-5B0C008C-5F92-4CAC-B21B-977ACE9FAD65Q34922363-8D10C57D-7DE3-4730-8F0A-ACBEB0FB665EQ35364351-D7B249B2-3C61-41D5-9506-6AC07151D860Q35598403-2AE9B663-77E8-4CA3-8CFC-563E1E9C74B8Q36089167-6FF0C715-078C-4435-A2DC-DA4F98002688Q36156077-124EBDFF-B88E-4171-802A-D4AA8C92AAD2Q36363261-F8B9D4CB-8BB1-4052-A750-1D356554B691Q37562099-C5EEA5FE-BF3E-48E1-955B-CA5C4653A515Q37563029-AA39A21D-7B27-4AF1-83A9-0FADAC20FDFFQ37636150-45154996-E182-49DE-8D85-0058CD7BAD84Q37872942-477ED57D-2BDD-4A8C-9A39-5380A3C05461Q37949391-618AB256-EE40-4D7F-ABD3-96995F32C0AEQ37996299-37BA2A63-B231-4EA6-840B-BCB581AC8D38Q38073892-9858F645-57AD-412F-BEF5-635CD49895F4Q38126768-FF78142F-3916-4E87-A766-9CE7EAE608CFQ40802708-990EA852-8E59-40DF-ADCE-80A69E5C8D1AQ41577365-F369789B-55F4-4078-80F1-9C2F0A2F0AD9Q41818495-DD10CF40-E84F-4F30-935D-F29296A1A645Q41949708-4AD3E417-6108-4D7A-84C2-C9C9CEDB0806Q42207939-F86BCF7A-5BBB-4DFA-A89F-BB2E42BA87FFQ44064611-432F3745-B9A2-4D09-9063-FA6512843FFDQ48657210-4C7A0102-E379-4F0E-88C5-BB7394749D72Q53689690-57905BEB-BD92-41BE-B505-01DFF541F038Q58797418-623E57B1-91DB-4841-897B-2C5F8B0A5075
P2860
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Activity of meropenem with and ...... a and Acinetobacter baumannii.
@en
type
label
Activity of meropenem with and ...... a and Acinetobacter baumannii.
@en
prefLabel
Activity of meropenem with and ...... a and Acinetobacter baumannii.
@en
P2093
P2860
P356
P1476
Activity of meropenem with and ...... a and Acinetobacter baumannii.
@en
P2093
Gengrong Lin
Glenn A Pankuch
Harald Seifert
Peter C Appelbaum
P2860
P304
P356
10.1128/AAC.00689-07
P407
P577
2007-10-29T00:00:00Z